offline
Eli Lilly Misses Q4 Earnings, Cuts 2019 Outlook After Loxo Oncology Deal
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
...
Eli Lilly said earnings for the three months ending in December came in at $1.33 per share, up 16.6% from the same period last year but just shy of the consensus forecast of $1.34. Group revenues, Eli Lilly said, were $6.438 billion, up nearly 4% from last year and ahead of the $6.28 billion forecast.
...
Looking into 2019, however, Eli Lilly said full year earnings would be in the range of $5.55 to $5.65 per share on a non-GAAP basis, down from its previous forecast of between $5.90 and $6.10, thanks to the Loxo purchase and a negative phase 3 confirmatory trial for its Lartruvo treatment for rare soft tissue cancers.
...
https://www.thestreet.com/investing/earn...yptr=yahoo
![[Bild: LLYc1dl1307.png]](https://finviz.com/publish/020619/LLYc1dl1307.png)
Eli Lilly posted weaker-than-expected fourth quarter earnings Tuesday, and lowered its 2019 profit guidance to reflect the impact of its planned acquisition of Loxo Oncology.
...
Eli Lilly said earnings for the three months ending in December came in at $1.33 per share, up 16.6% from the same period last year but just shy of the consensus forecast of $1.34. Group revenues, Eli Lilly said, were $6.438 billion, up nearly 4% from last year and ahead of the $6.28 billion forecast.
...
Looking into 2019, however, Eli Lilly said full year earnings would be in the range of $5.55 to $5.65 per share on a non-GAAP basis, down from its previous forecast of between $5.90 and $6.10, thanks to the Loxo purchase and a negative phase 3 confirmatory trial for its Lartruvo treatment for rare soft tissue cancers.
...
https://www.thestreet.com/investing/earn...yptr=yahoo
__________________
